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1.   Introduction: Influenza is an acute, contagious and usually self-limited febrile 
illness caused by infection of the respiratory tract with the influenza virus. The 
most common clinical manifestations are fever, malaise, and cough. The epidemic 
nature of influenza results in outbreaks every winter (seasonal influenza) but it is 
important to remember that the potential to become a pandemic always exists, as 
in the 2009 H1N1 influenza pandemic (this virus was a unique combination of influ-
enza virus genes never previously identified in either animals or people). Influenza 
viruses spread mainly by direct contact or inhalation of aerosols or large droplets 
from persons with influenza during a cough, sneeze or talk. Less often, infection is 
acquired from indirect contact of a person’s mouth, eyes or nose with contaminat-
ed environmental surfaces (fomites) that contain the viruses. The incubation period 
is 1-4 days (average: 2 days). The infective period begins 1 day before onset of 
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symptoms and extends to 5-7 days after becoming sick. Mortality from influenza infection is related 
mainly to its pulmonary complications.  
 
2. Know the enemy: Influenza viruses are RNA viruses that belong to the family Orthomyxoviri-
dae and are classified into three distinct types, influenza A, influenza B, and influenza C virus, on the 
basis of major antigenic differences. Influenza A viruses are further divided into subtypes on the ba-
sis of their hemagglutinin (HA) and neuraminidase (NA) activity (e.g., H1N1 or H3N2). Currently, 
infections during influenza season are usually caused by influenza types A (2009 H1N1), A (H3N2), 
and B. A recent CDC health advisory alerted clinicians about a number of reports of severe respira-
tory illness among young and middle-aged adults, many of whom were infected with influenza A 
(2009 H1N1) or pH1N1. Multiple pH1N1-associated hospitalizations, including many requiring in-
tensive care unit (ICU) admission, and some fatalities have been reported. The pH1N1 virus that 
emerged in 2009 caused more illness in children and young adults, compared to older adults, alt-
hough severe illness was seen in all age groups. While it is not possible to predict which influenza 
viruses will predominate during the entire 2013-14 season, pH1N1 has been the predominant circu-
lating virus so far. For the 2013-14 season, if pH1N1 virus continue to circulate widely, illness that 
disproportionately affects young and middle-aged adults may occur. Reports of new subtypes are in 
the news. For example, human infections with a new avian influenza A (H7N9) virus were first re-
ported in China in March 2013. Most of these infections are believed to result from exposure to 
infected poultry or contaminated environments. Most patients had a severe respiratory illness, with 
about one-third resulting in death. No cases of H7N9 outside of China have been reported. Influen-
za viruses that normally circulate in pigs are called “variant” viruses when they are found in humans. 
Influenza A H3N2 variant viruses (also known as “H3N2v” viruses) with the matrix (M) gene from 
the 2009 H1N1 virus were first detected in humans in July 2011. In 2012, 309 cases of H3N2v infec-
tion across 12 states were detected.  These infections have been mostly associated with prolonged 
exposure to pigs at agricultural fairs. Another subtype is the highly pathogenic avian influenza (HPAI) 
A (H5N1) virus. Human infections with this subtype are rare, although sporadic cases have been 
reported. Indonesia, Vietnam and Egypt have reported the highest number of human HPAI H5N1 
cases to date. The mortality rate is 60%. In the majority of cases, the person got HPAI H5N1 virus 
infection after direct or close contact with sick or dead infected poultry. This is one difference with 
H7N9, in which the infected poultry may be asymptomatic.  
 
3.  A little history: Influenza has caused pandemics as a result of antigenic shift (replacement of 
HA and NA) resulting in “new” viruses to which the population has no immunity. Only influenza A 
can experience antigenic shift. A pandemic can be devastating. In fact, the most significant infectious 
disease outbreak known to man was the Spanish Flu of 1918 that caused more than 50 million 
deaths; 50% of deaths were in people 20-40 years old. Other known influenza pandemics were the 
Asian Flu of 1957, the Hong Kong Flu of 1968, the Russian Flu of 1977 and the most recent 2009 
H1N1 Flu. 
 
4. Epidemiology: There are 25-50 million cases per seasonal influenza epidemic, causing more 
than 200,000 hospitalizations per year, more than 36,000 deaths per year and annual cost of ap-
proximately $87 billion. While any person is at risk of getting the infection, those older than 65 
years have increased rates of severe illness, hospitalization and death. American Indians, Alaskan Na-
tives, young children and pregnant women are also at increased risk of complications. Other co-
morbid conditions that predispose to complications are: asthma, neurological disorders (cerebral 
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palsy, epilepsy, stroke, muscular dystrophy, spinal cord injury), chronic lung disease (COPD, CF), 
cardiovascular disease (CHF, CAD), hematological disorders (sickle cell disease), diabetes mellitus, 
kidney disorders, liver disorders, immune deficiencies, BMI >40.  
 
 
5. Complications: Uncomplicated influenza illness typically resolves after 3-7 days in most cases, 
although cough and malaise can persist for >2 weeks. However, influenza virus infections can cause 
primary influenza viral pneumonia; exacerbate underlying medical conditions (e.g., pulmonary or car-
diac disease); lead to secondary bacterial pneumonia (typically Streptococcus pneumoniae and 
Staphylococcus aureus), sinusitis, or otitis media; or contribute to coinfections with other viral or 
bacterial pathogens. Influenza virus infection also has been uncommonly associated with encephalo-
pathy, transverse myelitis, myositis, myocarditis, pericarditis, and Reye syndrome. 
 
6. Diagnosis: Influenza illness can include any or all of these symptoms: fever, muscle aches, head-
ache, lack of energy, dry cough, sore throat, and runny nose. However, not everyone with influenza 
will have a fever. Respiratory illnesses caused by influenza virus infection are difficult to distinguish 
from illnesses caused by other respiratory pathogens on the basis of signs and symptoms alone. 
Hence, the differential diagnosis includes, but is not limited to, infections caused by Mycoplasma 
pneumoniae, Legionella spp., adenoviruses, RSV, rhinovirus, parainfluenza viruses, metapneumovirus. 
Sensitivity and predictive value of clinical definitions vary, depending on the prevalence of other res-
piratory pathogens and the level of influenza activity. For example, clinical assessment can have a 
positive predictive value up to 88% in adults living in areas with confirmed influenza virus circulation. 
Accurate and timely diagnosis of influenza is important because it can reduce the inappropriate use 
of antibiotics and provide the option of using early antiviral therapy. Several tests can help in the 
diagnosis of influenza as seen in the table below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method Acceptable specimens Test time 
Viral culture Nasopharyngeal swab 3-10 days 
  Throat swab   
  Bronchial wash   
  Sputum   
  Endotracheal aspirate   
Immunofluorescence Nasopharyngeal swab 1-4 hours 
Direct (DFA) or indirect (IFA) Bronchial wash   
  Endotracheal aspirate   
RT-PCR Nasopharyngeal swab 1-6 hours 
Singleplex or multiplex Throat swab   
  Bronchial wash   
  Sputum   
  Endotracheal aspirate   
Rapid influenza diagnostic tests Nasopharyngeal swab <30 minutes 
  Throat swab   
  Nasal wash   
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Influenza testing should be done when results will affect clinical decision making (for example, a hos-
pitalized patient with respiratory symptoms) and ideally within 4 days of onset of symptoms. The 
most commonly used testing method is the rapid antigen test, which provides results within 30 
minutes and is 50-70% sensitive when compared with viral culture or PCR. It is important to remem-
ber that false positives occur when prevalence is low (beginning/end of influenza season) and false 
negatives occur when prevalence is high. It is 90-95% specific. In other words, the rapid tests are 
useful for confirming infection with influenza but not for ruling out infection. If the rapid test is nega-
tive and clinical suspicion persists and a positive testing would change management, a molecular test 
such as the multiplex RT-PCR (commonly called “respiratory viral panel”) can be sent, which is more 
sensitive and has the advantage of testing for other respiratory viruses and bacteria (Influenza A, In-
fluenza A Subtypes H1, H1-2009, & H3, Influenza B, Parainfluenza Types 1, 2, 3, Respiratory Syncytial 
Virus, Human Metapneumovirus, Rhinovirus, Adenovirus, Bordetella pertussis, Chlamydophila pneu-
moniae, Mycoplasma pneumoniae, Coronavirus 229E, Coronavirus OC43, Coronavirus HKU1, and 
Coronavirus NL63). This is probably the preferred test in severely immunocompromised patients 
(e.g., stem cell transplant recipients) or critically ill patients with an unexplained respiratory illness.  
 
7. Treatment: Four antiviral drugs are available for treatment of influenza: M2 inhibitors 
(amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). The M2 in-
hibitors are active against influenza A only. Widespread M2 inhibitor resistance among influenza A 
(H3N2) virus strains has made this class less useful clinically. In addition, circulating 2009 H1N1 virus 
strains are resistant to M2 inhibitors. The neuraminidase inhibitors are active against influenza A and 
B. For the reasons above, only oseltamivir and zanamivir are currently recommended for use during 
the influenza season. Studies have shown that neuraminidase inhibitors reduce duration of symptoms 
by 1-1.5 days when administered within 2 days of illness onset. They also reduced risk of complica-
tions (pneumonia, hospitalization, respiratory failure, death). Antiviral therapy is indicated in any pa-
tient with influenza who: is hospitalized; has severe, complicated, or progressive illness; or is at high-
er risk for influenza complications (see Epidemiology). Although the greatest benefit is achieved when 
antiviral is started within 48 hours of illness onset, antiviral treatment might still be beneficial in pa-
tients with severe, complicated, or progressive illness and in hospitalized patient when administered 
>48 hours from illness onset. Decisions about starting antiviral treatment should not wait for labora-
tory confirmation of influenza. Antiviral treatment also can be considered for any previously healthy, 
symptomatic outpatient not at high risk with confirmed or suspected influenza on the basis of clinical 
judgment, if treatment can be initiated within 48 hours of illness onset.  
 
8. Postexposure prophylaxis: In randomized, placebo-controlled trials, both oseltamivir and 
zanamivir were efficacious in the prevention of influenza illness among persons who were adminis-
tered chemoprophylaxis after a household member or other close contact had laboratory-confirmed 
influenza. Postexposure chemoprophylaxis with neuraminidase inhibitors generally should be re-
served for those who have had recent close contact with a person with influenza. Antiviral chemo-
prophylaxis can be considered in family or close contacts of a person with a suspected or confirmed 
case if they are at higher risk for influenza complications and have not been vaccinated against influ-
enza at the time of exposure. Persons who receive an antiviral medication for chemoprophylaxis 
might still acquire influenza virus infection and be potentially able to transmit influenza virus, even if 
clinical illness is prevented. Decisions on whether to administer antivirals for chemoprophylaxis 
should take into account the exposed person's risk for influenza complications, the type and duration 
of contact, recommendations from local or public health authorities, and clinical judgment. Generally, 
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postexposure chemoprophylaxis for persons should be only used when antivirals can be started 
within 48 hours of the most recent exposure and is typically administered for a total of no more 
than 10 days after the most recent known exposure to a close contact known to have influenza. 
Chemoprophylaxis with antiviral medications is not a substitute for influenza vaccination when influ-
enza vaccine is available (see below). 
 
9. Influenza vaccination: According to the Advisory Committee on Immunization Practices 
(ACIP) for 2013-2014, routine annual influenza vaccination of all persons aged 6 months and older 
continues to be recommended. 2013-14 U.S. trivalent influenza vaccines contain an A/
California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype 
virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus (Yamagata lineage). Quadrivalent 
vaccines will include an additional vaccine virus, a B/Brisbane/60/2008-like virus (Victoria lineage). 
There are several vaccine products currently available in 5 categories: 
 
a. Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose 
b. Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose 
c. Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose 
d. Recombinant Influenza Vaccine, Trivalent (RIV3) 
e. Live-attenuated Influenza Vaccine, Quadrivalent (LAIV4) 
 
Please visit the Centers for Disease Control and Prevention (CDC) website for the complete list of 
vaccine products (www.cdc.gov). Other considerations: the IIV3 High Dose is recommended for 
people 65 years of age and older; it contains 4 times the dose of antigen compared to the standard 
dose for a better immunogenic response (studies showed 24.2% more effectiveness in this popula-
tion). The RIV3 is egg-free and can be used in people with history of severe allergic reactions to 
eggs, if aged 18-49 years. If the reaction is only hives, administer IIV and observe for reaction for at 
least 30 minutes. Women who are or will be pregnant during influenza season should receive IIV. 
Pregnant and postpartum women do not need to avoid contact with persons recently vaccinated 
with LAIV. Administration of IIV to persons receiving influenza antiviral drugs for treatment or 
chemoprophylaxis is acceptable. Inactivated vaccines do not interfere with the immune response to 
other inactivated vaccines or to live vaccines. 
 
10. Resources: The CDC website has a robust influenza section with information for health pro-
fessionals. I recommend checking regularly FluView, a weekly influenza surveillance report and case 
counts per region. You can also visit the Missouri Department of Health & Senior Services for week-
ly influenza reports in the state of Missouri. It provides information by county and comparisons with 
previous years. See the hyperlinks below. 
 
 
Useful References: 
 Centers for Disease Control and Prevention (CDC) website: www.cdc.gov/flu/professionals 
 FluView: www.cdc.gov/flu/weekly 
 Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP — 
United States, 2013–2014. MMWR; September 20, 2013 / 62(RR07);1-43. 
 MMWR: Evaluation of 11 Commercially Available Rapid Influenza Diagnostic Tests — United 
States, 2011–2012, November 2, 2012. MMWR; November 2, 2012 / 61(43);873-876. 
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 Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of 
the Advisory Committee on Immunization Practices (ACIP). MMWR; January 21, 2011/60
(RR01);1-24. 
 www.health.mo.gov/living/healthcondiseases/communicable/influenza/reports.php 
 Treanor, J. Influenza viruses, including avian influenza and swine influenza. In: Mandell, Douglas, 
and Bennett’s Principles and Practice of Infectious Diseases. 7th edition. Philadelphia: Chnurchill 
Livingston Elsevier. 2010. 
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ASH Choosing Wisely®:   
  
After attending the American Society of Hematology (ASH) meeting a few weeks ago, it is time to 
discuss the Choosing Wisely campaign®. This is a quality improvement project led by the American 
Board of Internal Medicine (ABIM) Foundation in collaboration with the leading national medical pro-
fessional societies.  This campaign aims to encourage open discussion among patients, physicians and 
the community regarding the costs and benefits of medical care, taking into account the increasing 
health care costs.  
  
The Choosing Wisely® campaign challenges medical societies to identify 5 tests, procedures, 
or  treatments within each specialty’s clinical domain that are offered to patients despite an absence 
of evidence demonstrating benefit or, in some cases, despite evidence demonstrating disutility or 
harm.   
 
ASH has identified 5 tests/intervention practices that can be improved and provided these recom-
mendation so the care provider teams actually consider the anticipated benefits of these interven-
tions before choosing to perform them. 
  
ASH Choosing Wisely® Recommendations:  
1. In situations where transfusion of RBCs is necessary, transfuse the minimum number of units re-
quired to relieve symptoms of anemia or to return the patient to a safe hemoglobin range (7-8 g/
dL in stable, non-cardiac in-patients) 
2. Do not test for thrombophilia in adult patients with venous thromboembolism occurring in the 
setting of major transient risk factors (surgery, trauma, or prolonged immobility) 
3. Do not use inferior vena cava filters routinely in patients with acute venous thromboembolism  
4. Do not administer plasma or prothrombin complex concentrates for non-emergent reversal of 
vitamin K antagonists (i.e., outside of the setting of major bleeding, intracranial hemorrhage, or 
anticipated emergent surgery) 
